Cargando…
Scientific Validation and Clinical Application of Lung Cancer Organoids
Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of nor...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616085/ https://www.ncbi.nlm.nih.gov/pubmed/34831235 http://dx.doi.org/10.3390/cells10113012 |
_version_ | 1784604262692552704 |
---|---|
author | Lee, Dahye Kim, Yoonjoo Chung, Chaeuk |
author_facet | Lee, Dahye Kim, Yoonjoo Chung, Chaeuk |
author_sort | Lee, Dahye |
collection | PubMed |
description | Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of normal cell organoids especially in LCOs from intrapulmonary lesions. Several modified media are specifically utilized for promoting the cancer cell’s growth. For culturing high-purity LCOs, cancer cells from metastatic lesions and malignant effusions are used. Recently, single-cell RNA sequencing has identified previously unknown cell populations in the lungs and lung cancer. This sequencing technology can be used to validate whether the LCO recapitulates the heterogeneity and functional hierarchy of the primary tumor. Several groups have attempted to culture LCOs with mesenchymal cells and immune cells to recapitulate the tumor microenvironment. Disease modeling using LCO provides novel insight into the pathophysiology of lung cancer and enables high-throughput screening for drug discovery and prognosis prediction. An LCO model would help to identify new concepts as a basis for lung cancer targeting by discovering innovative therapeutic targets. |
format | Online Article Text |
id | pubmed-8616085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86160852021-11-26 Scientific Validation and Clinical Application of Lung Cancer Organoids Lee, Dahye Kim, Yoonjoo Chung, Chaeuk Cells Review Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of normal cell organoids especially in LCOs from intrapulmonary lesions. Several modified media are specifically utilized for promoting the cancer cell’s growth. For culturing high-purity LCOs, cancer cells from metastatic lesions and malignant effusions are used. Recently, single-cell RNA sequencing has identified previously unknown cell populations in the lungs and lung cancer. This sequencing technology can be used to validate whether the LCO recapitulates the heterogeneity and functional hierarchy of the primary tumor. Several groups have attempted to culture LCOs with mesenchymal cells and immune cells to recapitulate the tumor microenvironment. Disease modeling using LCO provides novel insight into the pathophysiology of lung cancer and enables high-throughput screening for drug discovery and prognosis prediction. An LCO model would help to identify new concepts as a basis for lung cancer targeting by discovering innovative therapeutic targets. MDPI 2021-11-04 /pmc/articles/PMC8616085/ /pubmed/34831235 http://dx.doi.org/10.3390/cells10113012 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lee, Dahye Kim, Yoonjoo Chung, Chaeuk Scientific Validation and Clinical Application of Lung Cancer Organoids |
title | Scientific Validation and Clinical Application of Lung Cancer Organoids |
title_full | Scientific Validation and Clinical Application of Lung Cancer Organoids |
title_fullStr | Scientific Validation and Clinical Application of Lung Cancer Organoids |
title_full_unstemmed | Scientific Validation and Clinical Application of Lung Cancer Organoids |
title_short | Scientific Validation and Clinical Application of Lung Cancer Organoids |
title_sort | scientific validation and clinical application of lung cancer organoids |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616085/ https://www.ncbi.nlm.nih.gov/pubmed/34831235 http://dx.doi.org/10.3390/cells10113012 |
work_keys_str_mv | AT leedahye scientificvalidationandclinicalapplicationoflungcancerorganoids AT kimyoonjoo scientificvalidationandclinicalapplicationoflungcancerorganoids AT chungchaeuk scientificvalidationandclinicalapplicationoflungcancerorganoids |